

## Life Settlement Assets PLC – Ordinary Share D

### Investment Objective

The company's investment objective is to achieve capital appreciation by purchasing policies or portfolios of life settlement and mortality-related products in special or distressed situations

### Commentary

The trends in life expectancy ("LE") have been fundamentally changing. The rapid improvements in LE seen in the early years of the 21st century is now a thing of the past. Since 2015, average LE in the US gradually declined among all racial and ethnic groups, which included declines in nearly 12 preventable diseases and conditions. The US is not the only country experiencing lower LE. According to data from the UK's Institute and Faculty of Actuaries (IFOA), LE for both men and women in the UK is about five months lower than that in the organisation's previous model.

The Share Class D is reporting a performance of -1.48% for the month of January. The HIV segment registered \$9k on one policy, while the elderly segment registered about \$6k on one policy. Note that we have also been notified of an additional large maturity - the 1st largest exposure - for February. The Top 5 coverage table will be updated, and the related performance taken into account, in the forthcoming February monthly.

Investment Terms	Estimated NAV (USD)	NAV/Share
1.5% Management Fee	11,427,127.47	1.2297

Number Of Policies	Death Benefits (USD)	Matured Policies YTD*	Maturities YTD (USD)*
468	40 276 668	2	15 667

**Trust Investment Manager** Acheron Capital Ltd.

**Company Secretary** Maitland Administration Services Limited

**Administrator** Compagnie Européenne de Révision


**ISIN Ticker** GB00BF1Q4N27  
LSAD

**Auditor** Grant Thornton UK LLP


**Info** life@acheroncapital.com  
+44 207 258 5990

\*This figure refers to maturities occurred in the portfolio held by Avernus Portfolio Trust


Distribution by Age




Distribution by Death Benefit Amount<sup>(1)</sup>  
(USD)




Distribution by Gender




Distribution by Insurance Company



Distribution by Issue Date<sup>(2)</sup> (Yrs)



Maturities Since Inception




\* Capital and/or dividend payment(s)

(1) Indicates the available face amount to LSA which is a fractional interest of initial face amount.

(2) Distribution by issue dates reflects the time since the life insurance policy was issued.

Source of Data: Acheron Capital Ltd unless otherwise stated.


## Historical Maturity



## Maturities January 2019

Number of policies matured in January 2019	2	
Corresponding number of insured	2	
Total death benefit in January 2019(US\$)	15 667	
Valuation of Matured policies in Book (US\$)	5 259	
	<b>Average Age</b>	<b>Weighted Average Age</b>
HIV	59.0	58.9
Non-HIV	88.4	91.3

## Notification of Maturity



## Premiums Situation (US\$) <sup>(1)</sup>

Servicers Premiums Projection as of Beginning 2019	\$ 1.8M
Mortality Adjusted Premiums Projection Beginning 2019	\$ 1.7M
Estimated COI Net of Mortality Beginning 2019	\$ 1.8M

## Top 5 Coverage

Insured	Face (million)	Total Face (millions)	Age (ALB)	Expiration Age*
1	1.0/0.9/0.8	2.7	99	101/121/101
2	2.2	2.2	98	100
3	0.6/0.5/0.4	1.5	76	100/100/121
4	0.7/0.5/0.05/0.03	1.3	91	100/100/100/100
5	0.5/0.4	0.9	95	100/100

## Cash Situation (US\$) <sup>(1)</sup>

Cash at hand and similar	\$ 0.5M
Gross Cash in Policies <sup>(2)</sup> (estimated as of end 2018)	\$ 2.0M
Loan on Cash in Policies (estimated as of end 2018)	\$ 0
Net Cash in Policies <sup>(2)</sup> (estimated as of end 2018)	\$ 1.9M
Maturities to be received	\$ 2.3M

(1) Figures as provided by third parties

(2) Cash in a policy can typically be borrowed at an interest rate of 4% to 8%. Surrender charge included.

\* In case that one insured has more than one policy, their expiration ages are ordered by decreasing face.

Issued by Acheron Capital Limited, a company registered in England, no. 05588630 at Suite1, 3rd Floor, 11-12 St. James's Square, London SW1Y 4LB, England.

Acheron Capital Limited is authorized and regulated by the Financial Conduct Authority ("FCA") and appears on the FS Register under reference FRN 443685.

The investment products and services of Acheron Capital Limited are only available to professional clients and eligible counterparties; they are not available to retail clients. This document does not constitute an offer to buy or sell shares or units in any fund or funds managed or advised by Acheron Capital Limited. The prospectus of the funds is the only authorized document for offering shares or units in the funds. The prospectus may only be distributed in accordance with the laws and regulations of each appropriate jurisdiction in which any potential investor resides. Investors are also reminded that past performance should not be seen as an indication of future performance and that they may not get back the amount originally invested. UK Investors do not benefit from the Financial Services Compensation Scheme (FSCS). Investment in the funds carry risks which are more fully described in the prospectus. The funds are only suitable for sophisticated investors who are aware of the risks of investing in hedge funds.